Apr. 6 at 2:33 AM
$SLS 80K AML patients diagnosed each year - globally - remission rates exceed 80%. https://www.reddit.com/r/sellasLifescience/s/qhc2o2aYy3
- 56K obtain a first remission - the Viale-M
$ABBV setting.
+40,000 will benefit from Gps Immunotherapy - Mskcc Phase 2 MOS greater than 67.6 Months Not reached which is better than transplant and current SOC 28-35months.
- GPS PHASE 3 Approval for CR2, requires the entire Market add / include this CR1 patient setting to SLS’ Value.
40,000 with
$280K per patient Y1 rev
Y 2 + and up to 5 years - at
$110K
- DO THE MATH - and you’ll see why this
$0.73B manipulated equity will 10X and still have 2 Doubles in it for Vanguard and Blackrock.
